TITLE

Complete cystic fibrosis transmembrane conductance regulator gene sequencing in patients with idiopathic chronic pancreatitis and controls

AUTHOR(S)
Weiss, F. U.; Simon, P.; Bogdanova, N.; Mayerle, J.; Dworniczak, B.; Horst, J.; Lerch, M. M.
PUB. DATE
October 2005
SOURCE
Gut;Oct2005, Vol. 54 Issue 10, p1456
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene-many of which cause cystic fibrosis-have also been reported in patients with chronic pancreatitis. The authors examine whether mild or severe CFTR mutations, homozygous or compound heterozygous CFTR mutations, or even simple cystic fibrosis carrier status alone increases the risk of developing pancreatitis. Methods: After exclusion of patients with trypsinogen (PRSS1) mutations, cystic fibrosis, or pulmonary disease, and with known risk factors for pancreatitis 67 patients with idiopathic chronic pancreatitis (ICP) from northwest Germany and 60 geographically and ethnically matched controls were recruited. The entire coding region of the CFTR gene was sequenced in all patients and controls. ICP patients were also analysed for serine protease inhibitor Kazal type 1 (SPINK1) gene mutations. Results: Abnormal CFTR alleles were found to be twice as frequent in ICR patients as in controls (25/134 v 11/120; p<0.05). Three of four severe CFTR mutations detected in patients were compound heterozygous with another abnormal CFTR allele, whereas among controls three severe CFTR mutations were found in heterozygous cystic fibrosis carriers. In ICP patients 19 uncommon/mild mutations, including combinations of the 5T allele with 12TG repeats, were identified compared with only five in controls (p =0.012). Heterozygous SPINK1 mutations were detected in eight ICP patients (15% v 1 % in controls) but only one also carried an additional mild CFTR mutation. Conclusions: These data show that not only compound heterozygosity, but also cystic fibrosis carrier status for different types of CFTR mutations, including uncommon/mild mutations, significantly increase the risk of developing pancreatitis. Although 45% of the study's ICP patients carried predisposing genetic risk factors (for example, mutations in CFTR or SPINK1), the authors found no evidence that the risk conveyed by CFTR mutations depends on co-inherited SPINK1 mutations.
ACCESSION #
18457693

 

Related Articles

  • Endocytic adaptor complexes bind the C-terminal domain of CFTR. Weixel, K. M.; Bradbury, N. A. // Pflugers Archiv European Journal of Physiology;Nov2001 Supplement 1, Vol. 443, pS70 

    The cystic fibrosis transmembrane conductance regulator (CFTR) functions at the apical membrane of epithelial cells to regulate chloride permeability. Recent studies have shown that CFTR is rapidly and efficiently internalized from the plasma membrane. We have shown that such internalization is...

  • Genetic, Epidemiological, and Clinical Aspects of Hereditary Pancreatitis: A Population-Based Cohort Study in Denmark. Joergensen, Maiken Thyregod; Brusgaard, Klaus; Crüger, Dorthe Gylling; Gerdes, Anne-Marie; de Muckadell, Ove B. Schaffalitzky // American Journal of Gastroenterology;Aug2010, Vol. 105 Issue 8, p1876 

    OBJECTIVES:In a population-based, well-defined group of patients first regarded as having pancreatitis of unknown origin (PUO), we identified, described, and compared the clinical and genetic aspects of patients with hereditary pancreatitis (HP) and with cystic fibrosis transmembrane conductance...

  • Mutations in the SPINK1 gene in idiopathic pancreatitis Italian patients. Gomez-Lira, Macarena; Bonamini, Deborah; Castellani, Carlo; Unis, Lorenza; Cavallini, Giorgio; Assael, Baroukh Maurice; Pignatti, Pier Franco // European Journal of Human Genetics;Jul2003, Vol. 11 Issue 7, p543 

    Idiopathic chronic and acute recurrent pancreatitis (IP) have been associated with mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Mutations in the serine protease inhibitor Kazal 1 (SPINK1) have been described in some idiopathic chronic patients and it has been...

  • Symptomatic Pancreatitis in Patients With Cystic Fibrosis. Gooding, Ian; Bradley, Emma; Puleston, Joanne; Khin-Ma Gyi; Hodson, Margaret; Westaby, David // American Journal of Gastroenterology;Jun2009, Vol. 104 Issue 6, p1519 

    OBJECTIVES:A small group of cystic fibrosis (CF) patients develop symptomatic pancreatitis. The clinical characteristics of these cases are not well documented in the literature. Most cases are in pancreatic sufficient (PS) patients, but it is not clear whether pancreatitis does occur in...

  • Cystic fibrosis: addressing the transition from pediatric to adult-oriented health care. Kreindler, James L.; Miller, Victoria A. // Patient Preference & Adherence;2013, Vol. 7, p1221 

    Survival for patients with cystic fibrosis (CF) increased to nearly 40 years in 2012 from the early childhood years in the 1940s. Therefore, patients are living long enough to require transition from pediatric CF centers to adult CF centers. The goal of transition is for the young adult to be...

  • Making sense of the CF screening guidelines. Simpson, Joe Leigh // Contemporary OB/GYN;Oct2004, Vol. 49 Issue 10, p60 

    Provides practical advice on how to individualize the guidelines on cystic fibrosis screening. Pathogenesis and prevalence of the autosomal-recessive disorder; Signs and symptoms of cystic fibrosis; Identification of the genetic mutation that cause cystic fibrosis. INSET: Take-home messages.

  • Evidence that hereditary pancreatitis is genetically heterogeneous disorder. Ravnik-Glavač, Metka; Dean, Michael; Sant’Agnese, Paul di; Chernick, Mila; Koželj, Matjaž; Križman, Igor; Glavaž, Damjan // Pflugers Archiv European Journal of Physiology;Apr2000, Vol. 439 Issue 7, pr050 

    Hereditary pancreatitis (HP) is an autosomal dominant disorder characterized by recurrent acute attacks of severe abdominal pain with an onset in early childhood. Many HP patients progress to complicated chronic pancreatitis and/or pancreatic cancer. Initially, a single mutation R117H in the...

  • Electrodiffusional ATP movement through CFTR and other ABC transporters. Cantiello, H. F. // Pflugers Archiv European Journal of Physiology;Nov2001 Supplement 1, Vol. 443, pS22 

    The cystic fibrosis transmembrane conductance regulator (CFTR) is a member of the superfamily of ATP-binding cassette (ABC) transporters, also known as traffic ATPases. Recent studies from our laboratory determined that various members of the ABC family of transport proteins mediate the...

  • The CFTR-mediated protein secretion defect: pharmacological correction. McPherson, M. A.; Pereira, M. M. C.; Russell, D.; McNeilly, C. M.; Morris, R. M.; Stratford, F. L. L.; Dormer, R. L. // Pflugers Archiv European Journal of Physiology;Nov2001 Supplement 1, Vol. 443, pS121 

    The cystic fibrosis transmembrane conductance regulator (CFTR) mediates secretion of mucins and serous proteins. The aim was to correct pharmacologically the CFTR defect in protein secretion in airway gland cells and so to correct the viscous mucous secretions in cystic fibrosis (CF) airways and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics